{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:38:31Z","timestamp":1790775511909,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Iterum Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Urinary tract infections (UTIs), which are usually caused by bacteria in the Enterobacterales family, are a common reason for outpatient visits. Appropriate empiric therapy for UTIs requires an understanding of antibiotic resistance in the community. In this nationwide study, we examined trends in antibiotic resistance in urinary Enterobacterales isolates from ambulatory patients in the United States (US).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed the antimicrobial susceptibility profiles (extended-spectrum beta-lactamase [ESBL]-producing phenotype and not susceptible [NS] to beta-lactams, trimethoprim\/sulfamethoxazole [TMP\/SMX], fluoroquinolones [FQ], or nitrofurantoin [NFT]) of 30-day non-duplicate Enterobacterales isolates from urine cultures tested at ambulatory centers in the BD Insights Research Database (2011\u20132020). The outcome of interest was the percentage of resistant isolates by pathogen and year. Multi-variable generalized estimating equation models were used to assess trends in resistance over time and by additional covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 338 US facilities provided data for &gt;\u20092.2\u00a0million urinary Enterobacterales isolates during the 10-year study. Almost three-quarters (72.8%) of Enterobacterales isolates were\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      . Overall unadjusted resistance rates in Enterobacterales isolates were 57.5%, 23.1%, 20.6%, and 20.2% for beta-lactams, TMP\/SMX, FQ, and NFT, respectively, and 6.9% had an ESBL-producing phenotype. Resistance to two or more antibiotic classes occurred in 16.4% of isolates and 5.5% were resistant to three or more classes. Among isolates with an ESBL-producing phenotype, 70.1%, 59.9%, and 33.5% were NS to FQ, TMP\/SMX, and NFT, respectively. In multivariable models, ESBL-producing and NFT NS Enterobacterales isolates increased significantly (both P\u2009&lt;\u20090.001), while other categories of resistance decreased. High rates (\u2265\u200950%) of beta-lactam and NFT resistance were observed in\n                      <jats:italic>Klebsiella<\/jats:italic>\n                      isolates and in non-\n                      <jats:italic>E. coli<\/jats:italic>\n                      , non-\n                      <jats:italic>Klebsiella<\/jats:italic>\n                      Enterobacterales isolates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Antimicrobial resistance was common in urinary Enterobacterales isolates. Isolates with an ESBL-producing phenotype increased by about 30% between 2011 and 2020, and significant increases were also observed in NFT NS Enterobacterales isolates. Resistance rates for all four antibiotic classes were higher than thresholds recommended for use as empiric therapy. Non-\n                      <jats:italic>E. coli<\/jats:italic>\n                      Enterobacterales isolates showed high levels of resistance to commonly used empiric antibiotics, including NFT. These data may help inform empiric therapy choices for outpatients with UTIs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-022-07167-y","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T06:03:14Z","timestamp":1646028194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011\u20132020"],"prefix":"10.1186","volume":"22","author":[{"given":"Michael W.","family":"Dunne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven I.","family":"Aronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalvin C.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet A.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"7167_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/acem.12287","volume":"21","author":"L May","year":"2014","unstructured":"May L, Mullins P, Pines J. Demographic and treatment patterns for infections in ambulatory settings in the United States, 2006\u20132010. Acad Emerg Med. 2014;21:17\u201324.","journal-title":"Acad Emerg Med"},{"key":"7167_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/cid\/ciz764","volume":"70","author":"KJ Bruxvoort","year":"2020","unstructured":"Bruxvoort KJ, Bider-Canfield Z, Case JA, Qian L, Pressman A, Liang AS, et al. Outpatient urinary tract infections in an era of virtual healthcare: trends from 2008 to 2017. Clin Infect Dis. 2020;70:100\u20138.","journal-title":"Clin Infect Dis"},{"key":"7167_CR3","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103\u201320.","journal-title":"Clin Infect Dis"},{"key":"7167_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.diagmicrobio.2016.04.022","volume":"85","author":"SH Lob","year":"2016","unstructured":"Lob SH, Nicolle LE, Hoban DJ, Kazmierczak KM, Badal RE, Sahm DF. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010\u20132014. Diagn Microbiol Infect Dis. 2016;85:459\u201365.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"7167_CR5","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1128\/AAC.02897-15","volume":"60","author":"GV Sanchez","year":"2016","unstructured":"Sanchez GV, Babiker A, Master RN, Luu T, Mathur A, Bordon J. Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother. 2016;60:2680\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"7167_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijantimicag.2019.04.012","volume":"54","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Lagac\u00e9-Wiens PRS, Adam HJ, Baxter MR, Laing NM, Walkty AJ, et al. In vitro susceptibility of urinary isolates of Escherichia coli to first- and second-line empirically prescribed oral antimicrobial agents: CANWARD surveillance study results for Canadian outpatients from 2007 to 2016. Int J Antimicrob Agents. 2019;54:62\u20138.","journal-title":"Int J Antimicrob Agents"},{"key":"7167_CR7","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/cid\/ciab560","volume":"73","author":"KS Kaye","year":"2021","unstructured":"Kaye KS, Gupta V, Mulgirigama A, Joshi AV, Scangarella-Oman NE, et al. Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011\u20132019: rising ESBL strains and impact on patient management. Clin Infect Dis. 2021;73:1992\u20139.","journal-title":"Clin Infect Dis"},{"key":"7167_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.annemergmed.2018.05.006","volume":"72","author":"BW Frazee","year":"2018","unstructured":"Frazee BW, Trivedi T, Montgomery M, Petrovic DF, Yamaji R, Riley L. Emergency department urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: many patients have no identifiable risk factor and discordant empiric therapy is common. Ann Emerg Med. 2018;72:449\u201356.","journal-title":"Ann Emerg Med"},{"key":"7167_CR9","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1017\/ice.2018.254","volume":"39","author":"J Anesi","year":"2018","unstructured":"Anesi J, Lautenbach E, Nachamkin I, Garrigan C, Bilker WB, Omorogbe J, et al. Poor clinical outcomes associated with community-onset urinary tract infections due to extended-spectrum cephalosoporin-resistant Enterobacteriaceae. Infect Control Hosp Epidemiol. 2018;39:1431\u20135.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"7167_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/cid\/cix233","volume":"65","author":"O van Hecke","year":"2017","unstructured":"van Hecke O, Wang K, Lee JJ, Roberts NW, Butler CC. Implications of antibiotic resistance for patients\u2019 recovery from common infections in the community: a systematic review and meta-analysis. Clin Infect Dis. 2017;65:371\u201382.","journal-title":"Clin Infect Dis"},{"key":"7167_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02359-21","volume":"10","author":"MW Dunne","year":"2022","unstructured":"Dunne MW, Puttagunta S, Aronin SI, Brossette S, Murray J, Gupta V. Impact of empirical antibiotic therapy on outcomes of outpatient urinary tract infection due to non-susceptible Enterobacterales. Microbiol Spectr. 2022;10:e0235921. https:\/\/doi.org\/10.1128\/spectrum.02359-21.","journal-title":"Microbiol Spectr."},{"key":"7167_CR12","doi-asserted-by":"publisher","first-page":"ofw281","DOI":"10.1093\/ofid\/ofw281","volume":"4","author":"JE Simmering","year":"2017","unstructured":"Simmering JE, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM. The increase in hospitalizations for urinary tract infections and the associated costs in the United States, 1998\u20132011. Open Forum Infect Dis. 2017;4:ofw281.","journal-title":"Open Forum Infect Dis"},{"key":"7167_CR13","unstructured":"US Food and Drug Administration. FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. July 26, 2016. https:\/\/www.fda.gov\/media\/119537\/download. Accessed 20 May 2021."},{"key":"7167_CR14","doi-asserted-by":"publisher","first-page":"ofy241","DOI":"10.1093\/ofid\/ofy241","volume":"5","author":"E McCann","year":"2018","unstructured":"McCann E, Srinivasan A, DeRyke CA, DePestel DD, Murray J, Gupta V. Carbapenem-nonsusceptible Gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: a multicenter study. Open Forum Infect Dis. 2018;5:ofy241.","journal-title":"Open Forum Infect Dis"},{"key":"7167_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1186\/s12879-019-4387-3","volume":"19","author":"V Gupta","year":"2019","unstructured":"Gupta V, Ye G, Olesky M, Lawrence K, Murray J, Yu K. Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013\u20132017. BMC Infect Dis. 2019;19:742.","journal-title":"BMC Infect Dis"},{"key":"7167_CR16","doi-asserted-by":"publisher","first-page":"ofab063","DOI":"10.1093\/ofid\/ofab063","volume":"8","author":"V Gupta","year":"2021","unstructured":"Gupta V, Yu KC, Schranz J, Gelone SP. A multicenter evaluation of the US prevalence and regional variation in macrolide-resistant S. pneumoniae in ambulatory and hospitalized adult patients in the US. Open Forum Infect Dis. 2021;8:ofab063.","journal-title":"Open Forum Infect Dis"},{"key":"7167_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11255-019-02327-7","volume":"52","author":"J Dokter","year":"2020","unstructured":"Dokter J, Tennyson LE, Nguyen L, Han E, Sirls LT. The clinical rate of antibiotic change following empiric treatment for suspected urinary tract infections. Int Urol Nephrol. 2020;52:431\u20136.","journal-title":"Int Urol Nephrol"},{"key":"7167_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1017\/ice.2015.239","volume":"37","author":"JT Thaden","year":"2016","unstructured":"Thaden JT, Fowler VG, Sexton DJ, Anderson DJ. Increasing incidence of extended-spectrum \u03b2-lactamase-producing Escherichia coli in community hospitals throughout the southeastern United States. Infect Control Hosp Epidemiol. 2016;37:49\u201354.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"7167_CR19","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1017\/ice.2017.156","volume":"38","author":"J McDanel","year":"2017","unstructured":"McDanel J, Schweizer M, Crabb V, Nelson R, Samore M, Khader K, et al. Incidence of extended-spectrum \u03b2-lactamases (ESBL)-producing Escherichia coli and Klebsiella infections in the United States: a systematic literature review. Infect Control Hosp Epidemiol. 2017;38:1209\u201315.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"7167_CR20","doi-asserted-by":"publisher","first-page":"ofz164","DOI":"10.1093\/ofid\/ofz164","volume":"6","author":"EJ Weinstein","year":"2019","unstructured":"Weinstein EJ, Han JH, Lautenbach E, Nachamkin I, Garrigan C, Bilker WB, et al. A clinical prediction tool for extended-spectrum cephalosporin resistance in community-onset Enterobacterales urinary tract infection. Open Forum Infect Dis. 2019;6:ofz164.","journal-title":"Open Forum Infect Dis"},{"key":"7167_CR21","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12879-019-4363-y","volume":"19","author":"TP Lodise","year":"2019","unstructured":"Lodise TP, Bonine NC, Ye JM, Folse HJ, Gillard P. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections. BMC Infect Dis. 2019;19:718.","journal-title":"BMC Infect Dis"},{"key":"7167_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.annemergmed.2020.08.022","volume":"77","author":"DA Talan","year":"2021","unstructured":"Talan DA, Takhar SS, Krishmadasan A, Mower WR, Pallin DJ, Garg M, et al. Emergence of extended-spectrum beta-lactamase urinary tract infections among hospitalized emergency department patients in the United States. Ann Emerg Med. 2021;77:32\u201343.","journal-title":"Ann Emerg Med"},{"key":"7167_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.annemergmed.2021.01.003","volume":"78","author":"DG Mark","year":"2021","unstructured":"Mark DG, Hung YY, Salim Z, Tarlton NJ, Torres E, Frazee BW. Third-generation cephalosporin resistance and associated discordant antibiotic treatment in emergency department febrile urinary tract infections. Ann Emerg Med. 2021;78:357\u201369.","journal-title":"Ann Emerg Med"},{"key":"7167_CR24","doi-asserted-by":"publisher","first-page":"30220265","DOI":"10.1371\/journal.pone.0220265","volume":"14","author":"IA Critchley","year":"2019","unstructured":"Critchley IA, Cotroneo N, Pucci MJ, Mendes R. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS ONE. 2019;14:30220265.","journal-title":"PLoS ONE"},{"key":"7167_CR25","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.cmi.2017.12.026","volume":"24","author":"AJ Stewardson","year":"2018","unstructured":"Stewardson AJ, Vervoort J, Adriaenssens N, Coenen S, Godycki-Cwirko M, Kowalczyk A, et al. Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective study. Clin Microbiol Infect. 2018;24:972\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"7167_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.diagmicrobio.2019.02.007","volume":"94","author":"CS Forster","year":"2019","unstructured":"Forster CS, Powell EA, DeBurger B, Courter J, Haslam DB, Mortensen JE. Association of systemic antimicrobials with the expression of beta-lactamases in bacteria cultured from urological patients. Diagn Microbiol Infect Dis. 2019;94:391\u20134.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"7167_CR27","doi-asserted-by":"publisher","first-page":"e26558","DOI":"10.2196\/26558","volume":"23","author":"S Xu","year":"2021","unstructured":"Xu S, Glenn S, Sy L, Qian L, Hong V, Ryan DS, et al. Impact of the COVID-19 pandemic on health care utilization in a large integrated health care system: retrospective cohort study. J Med Internet Res. 2021;23:e26558.","journal-title":"J Med Internet Res"},{"key":"7167_CR28","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00192-020-04314-4","volume":"31","author":"CL Grimes","year":"2020","unstructured":"Grimes CL, Balk EM, Crisp CC, Antosh DD, Murphy M, Halder GE, et al. A guide for urogynecologic patient care utilizing telemedicine during the COVID-19 pandemic: review of existing evidence. Int Urogynecol J. 2020;31:1063\u201389.","journal-title":"Int Urogynecol J"},{"key":"7167_CR29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/cid\/cis509","volume":"55","author":"L Sun","year":"2012","unstructured":"Sun L, Klein EY, Laxminarayan R. Seasonality and temporal correlation between community antibiotic use and resistance in the United States. Clin Infect Dis. 2012;55:687\u201394.","journal-title":"Clin Infect Dis"},{"key":"7167_CR30","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1086\/660859","volume":"32","author":"PM Polgreen","year":"2011","unstructured":"Polgreen PM, Yang M, Laxminarayan R, Cavanaugh JE. Respiratory fluoroquinolone use and influenza. Infect Control Hosp Epidemiol. 2011;32:706\u20139.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"7167_CR31","doi-asserted-by":"publisher","first-page":"e0221133","DOI":"10.1371\/journal.pone.0221133","volume":"14","author":"EP Martinez","year":"2019","unstructured":"Martinez EP, Cepeda M, Jovanoska M, Bramer WM, Schoufour J, Gilsic M, et al. Seasonality of antimicrobial resistance rates in respiratory bacteria: a systematic review and meta-analysis. PLoS ONE. 2019;14:e0221133.","journal-title":"PLoS ONE"},{"key":"7167_CR32","doi-asserted-by":"publisher","unstructured":"Gupta V, Yu KC, Kabler H, Watts JA, Amiche A. Antibiotic resistance patterns and association with the influenza season in the United States: a multicenter evaluation reveals surprising associations between influenza season and resistance in Gram-negative pathogens. Open Forum Infect Dis. 2022. Manuscript online ahead of print. https:\/\/doi.org\/10.1093\/ofid\/ofac039.","DOI":"10.1093\/ofid\/ofac039"},{"key":"7167_CR33","unstructured":"Infectious Diseases Society of America. Medicare, Joint Commission update antimicrobial stewardship requirements. February 5, 2020. https:\/\/www.idsociety.org\/idsa-newsletter\/february-5-2020\/medicare-joint-commission-update-antimicrobial-stewardship-requirements\/. Accessed 1 Sept 2021."},{"key":"7167_CR34","doi-asserted-by":"publisher","first-page":"I236","DOI":"10.1136\/bmj.l236","volume":"364","author":"MC Gulliford","year":"2019","unstructured":"Gulliford MC, Prevost AT, Charlton J, Juszczyk D, Soames J, McDermott L, et al. Effectiveness and safety of electronically delivered prescribing feedback and decision support on antibiotic use for respiratory illness in primary care: REDUCE cluster randomized trial. BMJ. 2019;364:I236.","journal-title":"BMJ"},{"key":"7167_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/emp2.12029","volume":"1","author":"FR Goss","year":"2020","unstructured":"Goss FR, Bookman K, Barron M, Bickley D, Landgren B, Kroehl M, et al. Improved antibiotic prescribing using indication-based clinical decision support in the emergency department. J Am Coll Emerg Physicians Open. 2020;1:214\u201321.","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"7167_CR36","doi-asserted-by":"publisher","first-page":"e00675-18","DOI":"10.1128\/JCM.00675-18","volume":"57","author":"A Morand","year":"2019","unstructured":"Morand A, Cornu F, Dufour JC, Tsimaratos M, Lagier JC, Raoult D. Human bacterial repertoire of the urinary tract: a potential paradigm shift. J Clin Microbiol. 2019;57:e00675-18.","journal-title":"J Clin Microbiol"},{"key":"7167_CR37","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1017\/ice.2018.153","volume":"39","author":"A Shugart","year":"2018","unstructured":"Shugart A, Walters MS, Weiner LM, Lonsway D, Kallen AJ. Hospital microbiology laboratory practices for Enterobacteriaceae: Centers for Disease Control and Prevention National Healthcare Safety Network (NHSN) annual survey, 2015 and 2016. Infect Control Hosp Epidemiol. 2018;39:1115\u20137.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"7167_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.cmi.2020.07.027","volume":"27","author":"MM Sfeir","year":"2021","unstructured":"Sfeir MM. Adoption of the updated CLSI fluroquinolone breakpoints for Gram-negative bacteria in microbiology laboratories. Clin Microbiol Infect. 2021;27:308\u201310.","journal-title":"Clin Microbiol Infect"},{"key":"7167_CR39","doi-asserted-by":"crossref","first-page":"e00203-19","DOI":"10.1128\/JCM.00203-19","volume":"57","author":"RM Humphries","year":"2019","unstructured":"Humphries RM, Abbott AN, Hindler JA. Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories. J Clin Microbiol. 2019;57:e00203-19.","journal-title":"J Clin Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07167-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07167-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07167-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T20:44:44Z","timestamp":1674852284000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07167-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7167"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07167-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"assertion":[{"value":"8 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with all relevant guidelines and regulations, including the Declaration of Helsinki. Ethical approval for this study was received from the New England Institutional Review Board (Wellesley, Massachusetts; No. 120180023). Outcome studies using this retrospective, deidentified dataset were approved and informed consent was waived by the New England Institutional Review Board (Wellesley, Massachusetts; No. 120180023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MWD and SIA are employees of and own stock in\u00a0Iterum Therapeutics. KCY, JW, and VG are employees of Becton, Dickinson & Company, which was contracted by Iterum Therapeutics to conduct the study. KCY and VG also own stock in Becton, Dickinson & Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}